BrainStorm Cell Therapeutics to Announce Q2 Results and Corporate Update

NEW YORK, Aug. 7, 2024 – BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a prominent developer of adult stem cell therapeutics targeting neurodegenerative diseases, is set to hold a conference call to discuss its financial outcomes for the second quarter ending June 30, 2024. The call is scheduled for 8:30 a.m. Eastern Time on Wednesday, August 14, 2024, and will also include a corporate update.

Chaim Lebovits, the Chief Executive Officer of BrainStorm, will deliver the corporate update, followed by a Q&A session for participants. Other key executives joining Mr. Lebovits to address questions from the investment community include Haro Hartounian, Ph.D., the Chief Operating Officer; Bob Dagher, M.D., the Chief Medical Officer; and Alla Patlis, CPA, MBA, the Interim Chief Financial Officer.

Participants are encouraged to submit their questions ahead of the call by sending them to the provided email address, with a deadline for submissions set at 5:00 p.m. Eastern Time on Monday, August 12, 2024. The investment community can dial into the conference call using the provided toll-free and international numbers, along with the participant access code. A replay of the call will be available for 14 days post-event via specified toll-free and international numbers and a designated replay passcode.

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics is a foremost developer of novel autologous adult stem cell treatments for severe neurodegenerative diseases. The company holds exclusive rights to the NurOwn® technology platform, used to create autologous MSC-NTF cells, through a worldwide licensing agreement.

NurOwn® technology, which generates autologous MSC-NTF cells, has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for amyotrophic lateral sclerosis (ALS) treatment. BrainStorm has conducted a Phase 3 trial (NCT03280056) focusing on the safety and efficacy of repeated administrations of these cells in ALS patients. The trial received backing from the California Institute for Regenerative Medicine and additional grants from the ALS Association and I AM ALS.

Additionally, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) for progressive multiple sclerosis (MS) under an investigational new drug application. This trial was supported by the National MS Society (NMSS).

As a company devoted to advancing stem cell therapeutics, BrainStorm Cell Therapeutics aims to provide innovative treatment options for patients suffering from debilitating diseases. The company's research and development efforts continue to be supported by grants from notable organizations, emphasizing its commitment to clinical excellence and therapeutic innovation.